Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes.

Stefano CiardulloLaura SavaréFederico ReaGianluca PerseghinGiovanni Corrao

Published in: Diabetes/metabolism research and reviews (2024)

Higher adherence to drug treatment with GLP1-RA and SGLT2-I during the first year of the drug intake is associated with a lower incidence of adverse clinical outcomes in a real-world setting.

Keyphrases

rheumatoid arthritis
adverse drug
disease activity
risk factors
ankylosing spondylitis
glycemic control
drug induced
emergency department
replacement therapy
body mass index
skeletal muscle